Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2021 Dec 23

PMID 34938345

Citations 4

Authors

Tongji Xie

Zihua Zou

Chengcheng Liu

Yixiang Zhu

Ziyi Xu

Le Wang

Junling Li

Puyuan Xing

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to compare the efficacy of different first-line strategies based on different EGFR mutation types (19 deletion and 21 Leu858Arg mutations).

Methods: We conducted a systematic review and network meta-analysis (NMA) by searching and analyzing RCTs on PubMed, Embase, Cochrane Library, ASCO.org, and ESMO.org, from inception to September 30, 2020.

Results: Nineteen RCTs involving 5450 patients were finally included in this study, covering 10 different treatment strategies. The Bayesian ranking results suggested that, in terms of PFS, in the overall population and in patients with 19del mutation, osimertinib was most likely to rank the first, with the cumulative probabilities of 41.89% and 45.73%, respectively, while for patients with 21 Leu858Arg mutation, standard of care (SoC, represents first-generation EGFR-TKIs in this NMA) + chemotherapy was most likely to rank the first, with the cumulative probabilities of 30.81% in PFS. Moreover, SoC + chemotherapy provided the best overall survival benefit for the overall population and patients with 19del, with the cumulative probabilities of 57.85% and 33.51%, respectively. In contrast, for patients with 21 Leu858Arg mutation, dacomitinib showed the most favorable overall survival, with the cumulative probabilities of 36.73%.

Conclusions: In this NMA, osimertinib and SoC combined with chemotherapy would be the optimal first-line treatment options for advanced NSCLC patients harboring EGFR 19 deletion mutation and 21 Leu858Arg mutation, respectively. This finding is likely to be adopted in clinical practice and provide guidance for future clinical study design. Systematic review registration: INPLASY2020100059.

Citing Articles

Successful rapid improvement of acute respiratory distress syndrome induced by EGFR-mutated non-small cell lung cancer with almonertinib: a case report.

Sun C, Liang Z, Yan Z, Feng Y, Tang W, Wei S BMC Pulm Med. 2024; 24(1):471.

PMID: 39334060 PMC: 11437641. DOI: 10.1186/s12890-024-03292-3.

Successful therapy of a critically ill non-small cell lung cancer patient with compound mutations in G719X and S768I genes using furmonertinib: A case report.

Pan X, Shi M Heliyon. 2024; 10(5):e27106.

PMID: 38439894 PMC: 10909768. DOI: 10.1016/j.heliyon.2024.e27106.

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced -Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network....

Xue J, Li B, Wang Y, Huang Z, Liu X, Guo C Cancers (Basel). 2022; 14(19).

PMID: 36230817 PMC: 9563574. DOI: 10.3390/cancers14194894.

Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.

Xu Z, Liu C, Zhu Y, Zou Z, Xie T, Xing P BMC Cancer. 2022; 22(1):514.

PMID: 35525919 PMC: 9077975. DOI: 10.1186/s12885-022-09592-3.

References

Park K, Tan E, OByrne K, Zhang L, Boyer M, Mok T . Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016; 17(5):577-89. DOI: 10.1016/S1470-2045(16)30033-X. View

Cheng Y, Murakami H, Yang P, He J, Nakagawa K, Kang J . Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. J Clin Oncol. 2016; 34(27):3258-66. DOI: 10.1200/JCO.2016.66.9218. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I . Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive.... Ann Oncol. 2019; 30(12):1978-1984. DOI: 10.1093/annonc/mdz399. View

Salanti G, Ades A, Ioannidis J . Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2010; 64(2):163-71. DOI: 10.1016/j.jclinepi.2010.03.016. View

Yang C, Huang C, Yang C, Chu Y, Cheng A, Whang-Peng J . Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res. 2005; 65(15):6943-9. DOI: 10.1158/0008-5472.CAN-05-0641. View

Sequist L, Waltman B, Dias-Santagata D, Digumarthy S, Turke A, Fidias P . Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3(75):75ra26. PMC: 3132801. DOI: 10.1126/scitranslmed.3002003. View

Ghiringhelli F, Menard C, Puig P, Ladoire S, Roux S, Martin F . Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2006; 56(5):641-8. PMC: 11030569. DOI: 10.1007/s00262-006-0225-8. View

La Monica S, Madeddu D, Tiseo M, Vivo V, Galetti M, Cretella D . Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation. J Thorac Oncol. 2016; 11(7):1051-63. DOI: 10.1016/j.jtho.2016.03.006. View

10.

Mok T, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S . Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018; 36(22):2244-2250. DOI: 10.1200/JCO.2018.78.7994. View

11.

Knobloch K, Yoon U, Vogt P . Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg. 2010; 39(2):91-2. DOI: 10.1016/j.jcms.2010.11.001. View

12.

Lee C, Wu Y, Ding P, Lord S, Inoue A, Zhou C . Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. J Clin Oncol. 2015; 33(17):1958-65. DOI: 10.1200/JCO.2014.58.1736. View

13.

Jansen J, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N . Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011; 14(4):417-28. DOI: 10.1016/j.jval.2011.04.002. View

14.

Riely G, Pao W, Pham D, Li A, Rizvi N, Venkatraman E . Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(3 Pt 1):839-44. DOI: 10.1158/1078-0432.CCR-05-1846. View

15.

Yoshimura N, Okishio K, Mitsuoka S, Kimura T, Kawaguchi T, Kobayashi M . Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. J Thorac Oncol. 2012; 8(1):96-101. DOI: 10.1097/JTO.0b013e3182762bfb. View

16.

Jackman D, Yeap B, Sequist L, Lindeman N, Holmes A, Joshi V . Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(13):3908-14. DOI: 10.1158/1078-0432.CCR-06-0462. View

17.

Wu Y, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S . Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(11):1454-1466. DOI: 10.1016/S1470-2045(17)30608-3. View

18.

Hong S, Gao F, Fu S, Wang Y, Fang W, Huang Y . Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(5):739-742. PMC: 5885210. DOI: 10.1001/jamaoncol.2018.0049. View

19.

Alanazi A, Yunusa I, Elenizi K, Alzarea A . Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis. Lung Cancer Manag. 2020; 10(1):LMT43. PMC: 7724735. DOI: 10.2217/lmt-2020-0011. View

20.

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C . Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015; 26(9):1877-1883. DOI: 10.1093/annonc/mdv276. View